Join to view full profile
55 Fruit StBoston, MA 02114
Phone+1 617-724-4000
Dr. Piotrowska is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2012 - 2016- Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 2008 - 2011
Yale School of MedicineClass of 2008
Certifications & Licensure
MA State Medical License 2010 - 2027
American Board of Internal Medicine Medical Oncology
Clinical Trials
- Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer
- A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer Start of enrollment: 2017 Oct 31
- A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer Start of enrollment: 2018 Jan 31
Publications & Presentations
PubMed
- 1 citationsOsimertinib plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD.Sarah B Goldberg, Myung-Ju Ahn, Christina Baik, Javier De Castro Carpeño, Byoung Chul Cho
Clinical Cancer Research. 2026-10-01 - 3 citationsGenomic Profiling of Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer after Progression on First-line Osimertinib: Phase II ORCHARD Study.Helena A Yu, Kwan Ho Tang, Aleksandra Markovets, Ryan Hartmaier, Paul E Smith
Clinical Cancer Research. 2026-09-01 - 2 citationsDurvalumab plus etoposide-platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line o...Isamu Okamoto, Byoung Chul Cho, Sarah B Goldberg, Jonathan W Goldman, Adrianus J de Langen
Lung Cancer. 2026-08-01
Journal Articles
- Oxford University Press Has Registered This DOI Pre-PublicationR S Heist, Z Piotrowska, C G Azzoli, A T Shaw, I T Lennes, L V Sequist, J F Gainor, Oxford University Press
- EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung AdenocarcinomasLecia V Sequist, Zofia Piotrowska, Clinical Cancer Research
Press Mentions
A Combination of Savolitinib and Osimertinib Prolongs PFS in Patients with EGFR-Mutated NSCLC and Acquired MET Amplification After Progression on a First-Line EGFR TKIJanuary 16th, 2026- Withdrawn NSCLC Drug: Was Ambitious Phase 3 Trial Design to Blame?March 5th, 2025
- Medical Mysteries: She Went Undiagnosed Until Almost Too LateMay 25th, 2024
Grant Support
- Non-genomic resistance mechanisms in EGFR-mutant lung cancerMASSACHUSETTS GENERAL HOSPITAL2009–2027
Other Languages
- French, Polish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: